mSA2 affinity-enhanced biotin-binding CAR T cells for universal tumor targeting

mSA2 affinity-enhanced biotin-binding CAR T cells for universal tumor targeting

Blog Article

Chimeric antigen receptor T cells (CAR-Ts) are promising cancer therapeutics.However, since cancer cells can lose the CAR-targeted antigen and avoid destruction, targeting multiple antigens with multiple CARs has been proposed.We illustrate here a less cumbersome alternative, anti-tag CARs (AT-CARs) that bind to tags on tumor-targeting antibodies.We have created novel AT-CARs, using the affinity-enhanced monomeric streptavidin 2 (mSA2) tokidoki hello kitty blind box biotin-binding domain that when expressed on T cells can target cancer cells coated with biotinylated antibodies.

Human T cells expressing mSA2 CARs with CD28-CD3ζ and 4–1BB-CD3ζ signaling domains were activated by plate-immobilized biotin and by tumor cells coated with biotinylated antibodies against the tumor-associated antigens CD19 and CD20.Furthermore, mSA2 CAR T cells were capable of mediating cancer cell lysis and IFNγ production in an antibody dose-dependent manner.The mSA2 read more CAR is a universal AT-CAR that can be combined with biotinylated tumor-specific antibodies to potentially target many different tumor types.